The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Hi C-ckeye
There's a 10pm call, delayed to 10.30 as per the RNS.
GKP's management team will be hosting a presentation for analysts and investors at 10:00am (BST) today via live audio webcast:
https://brrmedia.news/GKP_HY23
Management will also be hosting an additional webcast presentation focused on retail investors via the Investor Meet Company ("IMC") platform at 12:00pm (BST) today. The presentation is open to all existing and potential shareholders and participants will be able to submit questions at any time during the event.
https://www.investormeetcompany.com/gulf-keystone-petroleum-ltd/register-investor
Investor Meets Company is at 12.00.
Recordings of both presentations will be made available on GKP's website.
KR
ZA
We now appear to have working capital for the next 18 months.
For me this is a significant derisk in terms of downward pressure on the share price.
The Bank of England has raised interest rates for the 14th consecutive time the cost of raising and paying for loans money etc has changed significantly since our last placing when money was cheap.
As it stands some posters want me to believe that Riverfort have invested £2mn at £1.03 with warrants at a 40% premium and now they are going to be focusing on shorting and creating death spirals. In addition to this investment strategy there's no guarantee that will need to take up more financing from Riverfort as SRA 737 on our compounds on trial could/ should potentially be in play in for revenue.
I need to go back to school.
KR
ZA
It's certainly been a very interesting if slightly stressful week or so from a price perspective.
As of 10.05 this morning we are at 450% of the daily average volume from a shares traded perspective.
We're going to find out sooner or later what the lie of the land really is.
KR
ZA
ZA
Hi Krusty
It's a nice problem to have for sure.
We know that SAR are always very understated in their comms, with regards to the 2 or more Pharma, we've got to be buoyed by the fact that a number of enquiries had been made re SRA737.
These discussions could easily lead to some parties not just tying up this but going for Sareum , Lock , stock & barrel.
KR
ZA
Whilst not in the same space or phase as aware Uk. It does demonstrate the appetite for Biotech
Astellas Pharma agreed to buy US biotech group Iveric Bio for roughly $5.9bn, marking the Japanese drugmaker’s largest-ever acquisition and giving it access to the rapidly expanding market for age-related eye diseases.
Astellas said on Monday that it would use cash and loans to buy the New Jersey-based company, formerly known as Ophthotech, for $40 per share, representing a premium of 22 per cent to the US company’s closing price on Friday.
KR
ZA